Can innate immunity be enhanced to treat microbial infections?

Nature Reviews Microbiology

Volumn 2, Issue 6, 2004, Pages 497-504

  Finlay, B Brett ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA INTERFERON; ANTIMICROBIAL CATIONIC PEPTIDE; BETA DEFENSIN; BETA DEFENSIN 1; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CATHELICIDIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; DNA; DROSOCIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYL LIPID A; POLYMYXIN B; PROTEGRIN; RIBAVIRIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; B LYMPHOCYTE ACTIVATION; BACTERIAL INFECTION; CELLULAR IMMUNITY; CONDYLOMA; DROSOPHILA; DRUG DESIGN; DRUG PROTEIN BINDING; GENE REARRANGEMENT; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOSTIMULATION; INFECTION CONTROL; LISTERIA MONOCYTOGENES; MACROPHAGE; MICROBIAL IMMUNITY; MOLLUSCUM CONTAGIOSUM; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; SIGNAL TRANSDUCTION; SKIN NECROSIS; STREPTOCOCCUS GROUP A; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION; WART VIRUS; ANIMAL; CPG ISLAND; IMMUNOLOGY; INFECTION; INNATE IMMUNITY; REVIEW;

BACTERIA (MICROORGANISMS); HEPATITIS C VIRUS; HUMAN PAPILLOMAVIRUS TYPES; LISTERIA; LISTERIA MONOCYTOGENES; STREPTOCOCCUS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CPG ISLANDS; HUMANS; IMMUNITY, NATURAL; INFECTION; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 2942670459     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro908     Document Type: Article

References (63)

1. Beutler, B. Innate immunity: an overview. Mol. Immunol. 40, 845-859 (2004).
2. Janeway, C. A. Jr & Medzhitov, R. Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
3. Athman, R. & Philpott, D. Innate immunity via Toll-like receptors and Nod proteins. Curr. Opin. Microbiol. 7, 25-32 (2004).
4. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424, 743-748 (2003).
5. Serbina, N. V. et al. Sequential MyD88-independent and -dependent activation of innate immune responses to intracellular bacterial infection. Immunity 19, 891-901 (2003).
6. Sugawara, I., Yamada, H., Mizuno, S., Takeda, K. & Akira, S. Mycobacterial infection in MyD88-deficient mice. Microbiol. Immunol. 47, 841-847 (2003).
7. Shi, S. et al. MyD88 primes macrophages for full-scale activation by interferon-γ yet mediates few responses to Mycobacterium tuberculosis. J. Exp. Med. 198, 987-997 (2003).
8. Tauszig-Delamasure, S., Bilak, H., Capovilla, M., Hoffmann, J. A. & Imler, J. L. Drosophila MyD88 is required for the response to fungal and Gram-positive bacterial infections. Nature Immunol. 3, 91-97 (2002).
9. Wells, C. A. et al. Genetic control of the innate immune response. BMC Immunol. 4, 5 (2003).
10. He, Y. W. et al. The extracellular matrix protein mindin is a pattern-recognition molecule for microbial pathogens. Nature Immunol. 5, 88-97 (2004).
11. Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076-2079 (2003).
12. Medvedev, A. E. et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521-531 (2003).
13. Kobayashi, K. S. & Flavell, R. A. Shielding the double-edged sword: negative regulation of the innate immune system. J. Leukoc. Biol. 75, 428-433 (2004).
14. Holland, S. M. et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon-γ. A preliminary report. N. Engl. J. Med. 330, 1348-1355 (1994).
15. Hengge, U. R. & Cusini, M. Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. Br. J. Dermatol. 149, S15-S19 (2003).
16. Persing, D. H. et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 10, S32-S37 (2002).
17. Ganz, T. Defensins: antimicrobial peptides of innate immunity. Nature Rev. Immunol. 3, 710-720 (2003).
18. Hancock, R. E. W. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1, 156-164 (2001).
19. Zasloff. M. Antimicrobial peptides of multicellular organisms. Nature 415, 389-395 (2002).
20. Hancock, R. E. W. & Devine, D. (eds) in Mammalian Host Defence Peptides. (Cambridge Univ. Press, New York, in the press).
21. Maxwell, A. I., Morrison, G. M. & Dorin, J. R. Rapid sequence divergence in mammalian β-defensins by adaptive evolution. Mol. Immunol. 40, 413-421 (2003).
22. Lynn, D. J., Lloyd, A. T., Fares, M. A. & O'Farrelly, C. Evidence of positively selected sites in mammalian α-defensins. Mol. Biol. Evol. 21, 819-827 (2004).
23. Emes, R. D., Goodstadt, L., Winter, E. E. & Ponting, C. P. Comparison of the genomes of human and mouse lays the foundation of genome zoology. Hum. Mol. Genetics 12, 701-709 (2003).
24. Nizet, V. et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414, 454-457 (2001).
25. Salzman, N. H., Ghosh, D., Huttner, K. M., Paterson, Y. & Bevins, C. L. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 422, 522-526 (2003).
26. Moser, C. et al. β-defensin 1 contributes to pulmonary innate immunity in mice. Infect. Immun. 70, 3068-3072 (2002).
27. Rosenberger, C. M., Gallo, R. L. & Finlay, B. B. Interplay between antibacterial effectors: a macrophage antimicrobial peptide impairs intracellular Salmonella replication. Proc. Natl Acad. Sci. USA 101, 2422-2427 (2004).
28. Zhang, L. & Falla, T. J. Cationic antimicrobial peptides - an update. Expert Opin. Investig. Drugs 13, 1-9 (2004).
29. Scott, M. G., Davidson, D. J., Gold, M. R., Bowdish, D. & Hancock, R. E. W. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 169, 3883-3891 (2002)
30. Rustici, A. et al. Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 259, 361-365 (1993).
31. Gray, B. H. & Haseman, J. R. Bactericidal activity of synthetic peptides based on the structure of the 55-kilodalton bactericidal protein from human neutrophils. Infect. Immun. 62, 2732-2739 (1994).
32. Hirata, M., Shimomura, Y., Yoshida, M., Wright, S. C. & Larrick, J. W. Endotoxin-binding synthetic peptides with endotoxin-neutralizing, antibacterial and anticoagulant activities. Progress Clin. Biol. Res. 388, 147-159 (1994).
33. Battafaraono, R. J. et al. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-α secretion in vitro. Surgery 118, 318-324 (1995).
34. Gough, M., Hancock, R. E. W. & Kelly, N. M. Anti-endotoxic potential of cationic peptide antimicrobials. Infect. Immun. 64, 4922-4927 (1996).
35. Chan, C. C., Tuaillon, N., Li, Q. & Shen, D. F. Therapeutic applications of antiflammin peptides in experimental ocular inflammation. Ann. NY Acad. Sci. 923, 141-146 (2000).
36. Tjabringa, G. S. et al. The antimicrobial peptide LL-37 activates innate immunity at the airway epithelial surface by transactivation of the epidermal growth factor receptor. J. Immunol. 171, 6690-6696 (2003).
37. Scott, M. G., Rosenberger, C. M., Gold, M. R., Finlay, B. B. & Hancock, R. E. W. An α-helical cationic antimicrobial peptide selectively modulates macrophage responses to lipopolysaccharide and directly alters macrophage gene expression. J. Immunol. 165, 3358-3365 (2000).
38. Hancock, R. E. W. & Diamond, G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8, 402-410 (2000).
39. Gudmundsson, G. H. & Agerberth, B. Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J. Immunol. Methods 232, 45-54 (1999).
40. Otte, J. M., Kiehne, K. & Herzig, K. H. Antimicrobial peptides in innate immunity of the human intestine. J, Gastroenterol. 38, 717-726 (2003).
41. Gallo, R. L., Murakami, M., Ohtake, T. & Zaiou, M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J. Allergy Clin. Immunol. 110, 823-831 (2002).
42. Biragyn, A. et al. Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2. Science 298, 1025-1029 (2002).
43. Davidson, D. J. et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 172, 1146-1156 (2004).
44. Bowdish, D. M. E., Davidson, D. J., Speert, D. P. & Hancock, R. E. W. The human cationic peptide LL-37 induces activation of the extracellular signal regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 172, 3758-3765 (2004).
45. Dong, C., Davis, R. J. & Flavell, R. A. MAP kinases in the immune response. Annu. Rev. Immunol. 20, 55-72 (2002).
46. De, Y. et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192, 1069-1074 (2000).
47. Niyonsaba, F. et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106, 20-26 (2002).
48. Oppenheim, J. J., Biragyn, A., Kwak, L. W. & Yang, D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 62, S17-S21 (2003).
49. van Wetering, S., Mannesse-Lazeroms, S. P., van Sterkenburg, M. A. & Hiemstra, P. S. Neutrophil defensins stimulate the release of cytokines by airway epithelial cells: modulation by dexamethasone. Inflamm. Res. 51, 8-15 (2002).
50. Yang, D. et al. Many chemokines including CCL20/MIP-3α display antimicrobial activity. J. Leukoc. Biol. 74, 448-455 (2003).
51. Dittmer, U. & Olbrich, A. R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Curr. Opin. Microbiol. 6, 472-477 (2003).
52. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
53. Liu, L., Zhou, X., Shi, J., Xie, X. & Yuan, Z. Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin. Immunology 110, 341-347 (2003).
54. Raghavan, S., Nystrom, J., Fredriksson, M., Holmgren, J. & Harandi, A. M. Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. Infect. Immun. 71, 7014-7022 (2003).
55. Verthelyi, D. & Klinman, D. M. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin. Immunol. 109, 64-71 (2003).
56. H1 responses in lethal murine leishmaniasis. J. Immunol. 160, 3627-3630 (1998).
57. Dalpke, A., Zimmermann, S. & Heeg, K. CpG DNA in the prevention and treatment of infections. BioDrugs 16, 419-431 (2002).
58. Elkins, K. L., Rhinehart-Jones, T. R., Stibitz, S., Conover, J. S. & Klinman, D. M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J. Immunol. 162, 2291-2298 (1999).
59. Lee, C. H., Jeong, H. D., Chung, J. K., Lee, H. H. & Kim, K. H. CpG motif in synthetic ODN primes respiratory burst of olive flounder Paralichthys olivaceus phagocytes and enhances protection against Edwardsiella tarda. Dis. Aquat. Organ. 56, 43-48 (2003).
60. Gomis, S. et al. Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect. Immun. 71, 857-863 (2003).
61. Rosenberger, C. M. & Finlay, B. B. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nature Rev. Mol. Cell Biol. 4, 385-396 (2003).
62. Hornef, M. W., Wick, M. J., Rhen, M. & Normark, S. Bacterial strategies for overcoming host innate and adaptive immune responses. Nature Immunol. 3, 1033-1040 (2002).
63. Hackett, C. J. Innate immune activation as a broad-spectrum biodefense strategy: prospects and research challenges. J. Allergy Clin. Immunol. 112, 686-694 (2003).